At SABCS, Presentations Highlight Ongoing Issues with Tamoxifen PGx

Although the studies presented at the San Antonio Breast Cancer Symposium did not resolve questions about the role of CYP2D6 genotypes or myriad other factors contributing to variability in tamoxifen metabolism, an oncologist at the Mayo Clinic offered some recommendations as to the types of studies that will be necessary to fill knowledge gaps in the field.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.